# Conference report from the 2015 OECI Oncology Days, Portugal, 22–24 June—tumour heterogeneity and next generation sequencing: morphology and technology **Authors:** Linda Cairns PMC · DOI: 10.3332/ecancer.2015.565 · ecancermedicalscience · 2015-08-19 ## TL;DR This conference report summarizes discussions on tumor heterogeneity from the 2015 OECI Oncology Days in Portugal. ## Contribution The paper provides a concise summary of expert insights on tumor heterogeneity and its clinical relevance. ## Key findings - Experts discussed clonal heterogeneity and its implications in cancer. - Phenotypic heterogeneity was highlighted as a key topic in the clinical setting. ## Abstract Tumour heterogeneity was the topic of the ‘Oncology Days’ series held at the 2015 OECI conference in which experts within the field provided an update on tumour heterogeneity and its relevance in the clinical setting. Here we present a summary of the presentations from the two major sessions of the meeting: clonal heterogeneity and phenotypic heterogeneity. ## Full-text entities - **Genes:** PDGFRB (platelet derived growth factor receptor beta) [NCBI Gene 5159] {aka CD140B, IBGC4, IMF1, JTK12, KOGS, OPDKD}, RTL1 (retrotransposon Gag like 1) [NCBI Gene 388015] {aka HUR1, MART1, Mar1, PEG11, SIRH2}, KRT20 (keratin 20) [NCBI Gene 54474] {aka CD20, CK-20, CK20, K20, KRT21}, BRF2 (BRF2 general transcription factor IIIB subunit) [NCBI Gene 55290] {aka BRFU, TFIIIB50}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, TTF1 (transcription termination factor 1) [NCBI Gene 7270] {aka TTF-1, TTF-I}, TYK2 (tyrosine kinase 2) [NCBI Gene 7297] {aka IMD35, JTK1}, GPC1 (glypican 1) [NCBI Gene 2817] {aka glypican}, VIM (vimentin) [NCBI Gene 7431], EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, OR51E2 (olfactory receptor family 51 subfamily E member 2) [NCBI Gene 81285] {aka HPRAJ, OR51E3P, OR52A2, PSGR}, ETV5 (ETS variant transcription factor 5) [NCBI Gene 2119] {aka ERM}, CD44 (CD44 molecule (IN blood group)) [NCBI Gene 960] {aka CDW44, CSPG8, ECM-III, ECMR-III, H-CAM, HCELL}, UBTF (upstream binding transcription factor) [NCBI Gene 7343] {aka CONDBA, NOR-90, UBF, UBF-1, UBF1, UBF2}, PRKCE (protein kinase C epsilon) [NCBI Gene 5581] {aka PKCE, nPKC-epsilon}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, ELK4 (ETS transcription factor ELK4) [NCBI Gene 2005] {aka SAP1}, KRT7 (keratin 7) [NCBI Gene 3855] {aka CK7, K2C7, K7, SCL}, SMAD4 (SMAD family member 4) [NCBI Gene 4089] {aka DPC4, JIP, MADH4, MYHRS}, FGFR3 (fibroblast growth factor receptor 3) [NCBI Gene 2261] {aka ACH, CD333, CEK2, HSFGFR3EX, JTK4}, ETV4 (ETS variant transcription factor 4) [NCBI Gene 2118] {aka E1A-F, E1AF, PEA3, PEAS3}, SLC45A3 (solute carrier family 45 member 3) [NCBI Gene 85414] {aka IPCA-2, IPCA-6, IPCA-8, IPCA6, PCANAP2, PCANAP6}, MST1 (macrophage stimulating 1) [NCBI Gene 4485] {aka D3F15S2, DNF15S2, HGFL, MSP, NF15S2}, ETV1 (ETS variant transcription factor 1) [NCBI Gene 2115] {aka ER81}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, FEV (FEV transcription factor, ETS family member) [NCBI Gene 54738] {aka HSRNAFEV, PET-1}, ERG (ETS transcription factor ERG) [NCBI Gene 2078] {aka LMPHM14, erg-3, p55}, PGR (progesterone receptor) [NCBI Gene 5241] {aka NR3C3, PR}, E2F3 (E2F transcription factor 3) [NCBI Gene 1871] {aka E2F-3}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, Kras (Kras proto-oncogene, GTPase) [NCBI Gene 16653] {aka K-Ras, K-Ras 2, K-ras, Ki-ras, Kras-2, Kras2}, EREG (epiregulin) [NCBI Gene 2069] {aka EPR, ER, Ep}, HOXB13 (homeobox B13) [NCBI Gene 10481] {aka HPC9, PSGD}, ERCC1 (ERCC excision repair 1, endonuclease non-catalytic subunit) [NCBI Gene 2067] {aka COFS4, RAD10, UV20}, Gpc1 (glypican 1) [NCBI Gene 14733], APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, ETS2 (ETS proto-oncogene 2, transcription factor) [NCBI Gene 2114] {aka ETS2IT1}, PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290] {aka CCM4, CLAPO, CLOVE, CWS5, HMH, MCAP}, ETV6 (ETS variant transcription factor 6) [NCBI Gene 2120] {aka TEL, TEL/ABL, THC5}, IL9 (interleukin 9) [NCBI Gene 3578] {aka HP40, IL-9, P40}, MSH2 (mutS homolog 2) [NCBI Gene 4436] {aka COCA1, FCC1, HNPCC, HNPCC1, LCFS2, LYNCH1}, ALK (ALK receptor tyrosine kinase) [NCBI Gene 238] {aka ALK1, CD246, NBLST3}, TSC1 (TSC complex subunit 1) [NCBI Gene 7248] {aka LAM, TSC}, DSN1 (DSN1 component of MIS12 kinetochore complex) [NCBI Gene 79980] {aka C20orf172, KNL3, MIS13, dJ469A13.2, hKNL-3}, BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675] {aka BRCC2, BROVCA2, FACD, FAD, FAD1, FANCD}, SLTM (SAFB like transcription modulator) [NCBI Gene 79811] {aka Met}, PROM1 (prominin 1) [NCBI Gene 8842] {aka AC133, CD133, CORD12, MCDR2, MSTP061, PROML1}, GRPR (gastrin releasing peptide receptor) [NCBI Gene 2925] {aka BB2, BB2R, BRS2}, DCT (dopachrome tautomerase) [NCBI Gene 1638] {aka OCA8, TRP-2, TYRP2}, KDR (kinase insert domain receptor) [NCBI Gene 3791] {aka CD309, FLK1, VEGFR, VEGFR2}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, GATA3 (GATA binding protein 3) [NCBI Gene 2625] {aka HDR, HDRS}, FLI1 (Fli-1 proto-oncogene, ETS transcription factor) [NCBI Gene 2313] {aka BDPLT21, EWSR2, FLI-1, SIC-1} - **Diseases:** basal type urothelial carcinoma (MESH:D002280), invasive (MESH:D009361), sarcomatoid carcinomas (MESH:D002292), leukaemia (MESH:D015458), HD (MESH:D006816), inflammatory (MESH:D007249), gastric cancer (MESH:D013274), adenocarcinomas (MESH:D000230), Urothelial carcinoma of the bladder (MESH:D001749), hyperplasia (MESH:D006965), pancreas cancer (MESH:D010190), Urothelial carcinoma (MESH:D014523), Metastases (MESH:D009362), RB (MESH:D012175), muscle invasive and metastasising disease (MESH:D000093284), dysplasias (MESH:D015792), rare tumours (MESH:D035583), basal like tumours (MESH:D009369), carcinoma in situ (MESH:D002278), signet ring cell adenocarcinoma (MESH:D018279), NSCLC (MESH:D002289), Breast cancer (MESH:D001943), benign pancreatic disease (MESH:D010182), epidermoid carcinoma (MESH:D002294), pleomorphic carcinomas (MESH:D008949), CRC (MESH:D015179), TMA (MESH:D017695), Melanoma (MESH:D008545), aneuploidy (MESH:D000782), mesenchymal tumour (MESH:D008637), panurothelial disease (MESH:D004194), Lung Cancer (MESH:D008175), prostate cancer (MESH:D011471), rectal cancer (MESH:D012004), adenosquamous carcinomas (MESH:D018196), familial prostate cancer (MESH:C537243), lymph node metastases (MESH:D008207), breast and colon (MESH:D061325), PCa (MESH:D011472), large cell carcinomas (MESH:D018287), Ewing sarcoma (MESH:D012512) - **Species:** Nicotiana tabacum (American tobacco, species) [taxon 4097], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090] - **Mutations:** I767M - **Cell lines:** LNCaP — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_0395), VCaP — Homo sapiens (Human), Prostate carcinoma, Cancer cell line (CVCL_2235) ## Full text _Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC4544576/full.md ## Figures 1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC4544576/full.md ## References 25 references — full list in the complete paper: https://tomesphere.com/paper/PMC4544576/full.md --- Source: https://tomesphere.com/paper/PMC4544576